<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Genetic defects in thyroid hormone transport and metabolism
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Genetic defects in thyroid hormone transport and metabolism
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Genetic defects in thyroid hormone transport and metabolism
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Samuel Refetoff, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Alexandra M Dumitrescu, MD, PhD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            David S Cooper, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Douglas S Ross, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Alison G Hoppin, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jan 25, 2024.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1173991787">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Genetic defects in thyroid hormone transport and metabolism are rare causes of impaired sensitivity to thyroid hormone. These conditions are characterized by abnormal relative concentrations of triiodothyronine (T3), thyroxine (T4), and reverse T3 (rT3), with diverse clinical manifestations.
        </p>
        <p>
         There are two main categories:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Thyroid hormone cell membrane transport defect (THCMTD) – Impaired uptake of thyroid hormone into selected target cells due to
         <em>
          MCT8
         </em>
         gene mutations
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Thyroid hormone metabolism defect (THMD) – Impaired conversion of T4 to T3 in the cytoplasm of cells dependent on this process
        </p>
        <p>
        </p>
        <p>
         These disorders will be discussed below. Other inherited disorders in which the secretion or action of thyroid hormone is impaired are far more common and are discussed separately:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5845.html" rel="external">
          "Resistance to thyrotropin and thyrotropin-releasing hormone"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5827.html" rel="external">
          "Resistance to thyroid hormone and other defects in thyroid hormone action"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3048554682">
         <span class="h1">
          MECHANISMS OF IMPAIRED SENSITIVITY
         </span>
         <span class="headingEndMark">
          —
         </span>
         The normal physiology of thyroid hormone production and action is summarized in the figure and a separate topic review  (
         <a class="graphic graphic_figure graphicRef70604" href="/z/d/graphic/70604.html" rel="external">
          figure 1
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/5827.html" rel="external">
          "Resistance to thyroid hormone and other defects in thyroid hormone action", section on 'Normal thyroid hormone physiology'
         </a>
         .)
        </p>
        <p>
         Several different mechanisms that cause impaired sensitivity to thyroid hormone have been described, and others are postulated. A classification and proposed nomenclature is outlined below  (
         <a class="graphic graphic_table graphicRef110783" href="/z/d/graphic/110783.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid1">
          1-3
         </a>
         ]. These defects should be considered in a patient with thyroid function tests that show a discrepancy of serum thyroid hormone and thyrotropin (thyroid-stimulating hormone [TSH]) concentrations, and each defect has its own constellation of test abnormalities and a different clinical presentation. The types of known defects are listed below according to the physiologic sequence of thyroid hormone cell transport, metabolism, and action rather than by clinical frequency.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Thyroid hormone cell membrane transport defect (THCMTD)
         </strong>
         – Defects in one of the cell membrane transport proteins that allow thyroid hormone to enter cells cause reduced intracellular levels of thyroid hormone. Defective cell transport proteins may not reach their normal location on cell membrane or may not be able to transport the hormone. The resulting disorder depends on the specific hormone transporter affected.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The only known THCMTD is caused by a mutation in the
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F300095&amp;token=tEpDslnpc0F0kICl%2Fz7sFfZgq3tROP1vh4DhckKBw6F5tL%2FncynfxeB6L69JsnBL&amp;TOPIC_ID=132665" target="_blank">
          <i>
           MCT8
          </i>
         </a>
         gene, which is characterized by elevated serum concentrations of triiodothyronine (T3) and low levels of thyroxine (T4) and reverse T3 (rT3) as well as a severe psychomotor deficit [
         <a href="#rid4">
          4
         </a>
         ]. Lacking MCT8 function in humans alters thyroid hormone availability in the brain, which does not seem to be compensated by the presence of other thyroid hormone transporters  (
         <a class="graphic graphic_figure graphicRef134207" href="/z/d/graphic/134207.html" rel="external">
          figure 2
         </a>
         ). This transporter is also involved in the secretion of thyroid hormone from the thyroid gland and uptake by the kidney [
         <a href="#rid5">
          5,6
         </a>
         ]. (See
         <a class="local">
          'Thyroid hormone cell membrane transport defect'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Thyroid hormone metabolism defect (THMD)
         </strong>
         – T4, the major product secreted by the thyroid gland, is a prohormone that must be activated by conversion to T3. Defects in any of the factors involved in this enzymatic deiodination reaction can cause diminished production of T3 and thus reduced availability of active thyroid hormone in tissues that depend upon the circulating T4 for local generation of T3. Known defects include mutations in the
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F607693&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyomqREgOjVrHi55WTEYHmvg&amp;TOPIC_ID=132665" target="_blank">
          <i>
           SBP2
          </i>
         </a>
         gene (also known as
         <em>
          SECISBP2
         </em>
         [selenocysteine insertion sequence-binding protein 2]) resulting in reduced selenoprotein synthesis including the three deiodinases or in mutations in the
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F147892&amp;token=tEpDslnpc0F0kICl%2Fz7sFYR8Q1aXDxBReNYTLBTBwCShJIgpOf1wdXmUBJA9UBAO&amp;TOPIC_ID=132665" target="_blank">
          <i>
           DIO1
          </i>
         </a>
         gene  (
         <a class="graphic graphic_figure graphicRef134209" href="/z/d/graphic/134209.html" rel="external">
          figure 3
         </a>
         ). Both disorders are characterized by an increased rT3:T3 ratio. (See
         <a class="local">
          'Thyroid hormone metabolism defect'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Thyroid hormone action defects
         </strong>
         – Defects in thyroid hormone action are called resistance to thyroid hormone (RTH) and are usually due to a mutation in one of the genes encoding the thyroid hormone receptor. The types and clinical characteristics of RTH are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/5827.html" rel="external">
          "Resistance to thyroid hormone and other defects in thyroid hormone action"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2443332836">
         <span class="h1">
          THYROID HORMONE CELL MEMBRANE TRANSPORT DEFECT
         </span>
         <span class="headingEndMark">
          —
         </span>
         Mutations in the
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F300095&amp;token=87jLzclRwWxNoI%2BQq5Gg777eE%2F3d0TdyiA30Y9NC13O4PCI7jJzYhrpF3PxWs%2BQd&amp;TOPIC_ID=132665" target="_blank">
          <i>
           MCT8
          </i>
         </a>
         gene cause an X chromosome-linked syndrome combining severe psychoneuromotor deficiency and characteristic abnormalities of thyroid function tests. The early hallmarks are hypotonia and high serum triiodothyronine (T3) levels in boys.
        </p>
        <p class="headingAnchor" id="H2227632470">
         <span class="h2">
          Prevalence and inheritance
         </span>
         <span class="headingEndMark">
          —
         </span>
         The incidence of a thyroid hormone cell membrane transport defect (THCMTD) is not known. This X-linked form of intellectual disability with neuromotor disabilities was first described in 1944 and subsequently named the Allan-Herndon-Dudley syndrome [
         <a href="#rid7">
          7
         </a>
         ]. In 2004, the syndrome was shown to manifest characteristic thyroid function abnormalities and to be caused by
         <em>
          MCT8
         </em>
         gene mutations [
         <a href="#rid4">
          4,8
         </a>
         ]. Since then, more than 300 individuals belonging to more than 137 families with
         <em>
          MCT8
         </em>
         defects were identified, suggesting that this syndrome is more common than initially suspected [
         <a href="#rid9">
          9-12
         </a>
         ] (and personal observations). Spontaneous
         <em>
          MCT8
         </em>
         mutations can be maintained in the population because carrier females are asymptomatic; thus, no negative selection takes place.
        </p>
        <p>
         The diagnosis of THCMTD is often delayed because the clinical symptoms are more suggestive of a neurologic defect rather than the consequence of a defect in thyroid hormone availability. Further, neonatal screening for thyroid hormone deficiency is based on the measurement of thyroid-stimulating hormone (TSH). A method for newborn screening has been proposed, consisting of measuring iodothyronines in dried blood spots [
         <a href="#rid13">
          13
         </a>
         ]. This approach could become important for early diagnosis and for determining the prevalence of this condition. (See
         <a class="local">
          'Treatment'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H2491659764">
         <span class="h2">
          Pathogenesis
         </span>
         <span class="headingEndMark">
          —
         </span>
         <em>
          MCT8
         </em>
         , also known as
         <em>
          SLC16A2
         </em>
         (
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F300095&amp;token=87jLzclRwWxNoI%2BQq5Gg777eE%2F3d0TdyiA30Y9NC13O4PCI7jJzYhrpF3PxWs%2BQd&amp;TOPIC_ID=132665" target="_blank">
          MIM 300095
         </a>
         ), encodes monocarboxylate acid transporter 8, which transports thyroxine (T4) and T3 into cells, as shown in the figure  (
         <a class="graphic graphic_figure graphicRef134207" href="/z/d/graphic/134207.html" rel="external">
          figure 2
         </a>
         ) [
         <a href="#rid14">
          14
         </a>
         ]. This transporter plays an important role in the movement of thyroid hormone into the brain and is thus critical to the effect of thyroid hormone on brain development [
         <a href="#rid15">
          15
         </a>
         ].
        </p>
        <p>
         The main clinical manifestations of MCT8 deficiency are caused by thyroid hormone deprivation, particularly in the brain during embryonic life [
         <a href="#rid16">
          16
         </a>
         ]. Indeed, the severity of the psychomotor retardation is correlated with the degree of functional impairment of the mutant transporter [
         <a href="#rid17">
          17
         </a>
         ]. Several types of defects in MCT8 can interfere with its function as a carrier protein, including reduced protein expression, impaired trafficking to plasma membrane, or reduced substrate affinity.
        </p>
        <p>
         MCT8 defects are characterized by an unusual mixed pattern of thyroid hormone deprivation in some tissues and thyroid hormone excess in others. Transgenic mice deficient in Mct8 have thyroid function test abnormalities similar to those of humans with
         <em>
          MCT8
         </em>
         mutations and provide insight into the mechanisms responsible for the thyroid phenotype [
         <a href="#rid18">
          18-20
         </a>
         ]. In this animal model, tissue levels of T3 varied depending on redundancy in thyroid hormone transmembrane transporters; liver T3 concentrations were high, and brain T3 concentrations were low. The resulting increase in liver type 1 deiodinase and brain type 2 deiodinase enhances the generation of T3 and has a consumptive effect on T4. In addition, the impaired T3 uptake in some tissues, such as the brain, prevents its degradation by type 3 deiodinase. Another study in mice demonstrated that
         <em>
          Mct8
         </em>
         gene defects also cause impaired thyroid hormone secretion from the thyroid gland [
         <a href="#rid5">
          5
         </a>
         ], suggesting for the first time that MCT8 mediates the molecular mechanism of thyroid hormone secretion, a process previously believed to be passive.
        </p>
        <p>
         In addition to monocarboxylate transporters such as MCT8, other transport proteins belonging to different families of solute carriers, organic anions, and amino acids participate in the transport of thyroid hormone across cell membranes. It has been postulated that defects in some of these other transport proteins also could cause reduced sensitivity to thyroid hormone, but such mutations have not yet been identified [
         <a href="#rid21">
          21
         </a>
         ]. Each transport protein has a distinctive role in the cell-specific delivery of thyroid hormone due to differences in cell distribution and kinetics as well as transport of other ligands [
         <a href="#rid22">
          22
         </a>
         ]. Presumably, defects in each transport protein would result in a distinct phenotype.
        </p>
        <p class="headingAnchor" id="H2152943374">
         <span class="h2">
          Clinical features
         </span>
         <span class="headingEndMark">
          —
         </span>
         Because
         <em>
          MCT8
         </em>
         defects are X-linked, virtually all affected individuals are male. A female patient has been described with a phenotype identical to that of affected males, caused by a de novo balanced translocation involving the
         <em>
          MCT8
         </em>
         locus [
         <a href="#rid12">
          12
         </a>
         ].
        </p>
        <p>
         The clinical phenotype, including thyroid test abnormalities, varies in severity but is otherwise quite consistent among affected individuals. Affected individuals have stigmata of thyroid hormone deficiency as well as excess. These include psychomotor abnormalities, which are caused by thyroid hormone deficiency in the brain, and a hypermetabolic state and difficulty to maintain weight, which are caused by T3 excess in some other tissues. This coexistence of thyroid hormone deficiency and excess in the same individual is due to cell-specific differences in the expression of the various thyroid hormone transporters. (See
         <a class="local">
          'Pathogenesis'
         </a>
         above.)
        </p>
        <p>
         Gestation and birth are normal, and affected newborns have normal length, weight, and head circumference. Early signs, manifesting in the first few weeks of life, are hypotonia and feeding difficulties, followed by other neurodevelopmental abnormalities presenting during infancy or early childhood. Many infants have characteristic paroxysms of kinesigenic dyskinesias, consisting of body extension, opening of the mouth, and stretching or flexing of the limbs [
         <a href="#rid23">
          23
         </a>
         ]. These paroxysms are usually triggered by somatosensory stimuli and last a few minutes or less. True seizures also can occur.
        </p>
        <p>
         With advancing age, weight gain lags, while linear growth proceeds normally. Although truncal hypotonia persists, there is progressive development of limb rigidity, often resulting in spastic quadriplegia. Muscle mass is diminished and there is generalized muscle weakness with poor head control. Purposeless movements are common. A case series of children evaluated by video electroencephalogram described repetitive sleep starts (nonepileptic bilateral limb contractions during rapid eye movement sleep) in all four children studied and seizures in three [
         <a href="#rid24">
          24
         </a>
         ]. Most affected children are never able to sit by themselves or walk and have no speech. Although early death has occurred in some families, some individuals live beyond the age of 70 years.
        </p>
        <p>
         Female carriers do not manifest any of the psychomotor abnormalities described above.
        </p>
        <p>
         In a retrospective study of 151 patients with 73 different
         <em>
          MCT8
         </em>
         mutations, the median age at diagnosis was 24 months and the median overall survival was 35 years [
         <a href="#rid25">
          25
         </a>
         ]. Thirty-two of 151 patients died; the main causes of mortality were pulmonary infection and sudden death in six patients each. The risk of death was higher in individuals who did not attain head control by age 1.5 years and those who were underweight between ages one and three years compared with those who had head control and normal body weight at this age.
        </p>
        <p class="headingAnchor" id="H1479426102">
         <span class="h2">
          Laboratory findings
         </span>
         <span class="headingEndMark">
          —
         </span>
         Individuals with
         <em>
          MCT8
         </em>
         gene defects have characteristically high serum T3 and low reverse T3 (rT3) concentrations, in contrast with the other three syndromes of impaired sensitivity to thyroid hormone  (
         <a class="graphic graphic_table graphicRef50619" href="/z/d/graphic/50619.html" rel="external">
          table 2
         </a>
         ). T4 tends to be low, and TSH levels are normal or slightly elevated. Heterozygous female carriers have serum thyroid hormone concentrations intermediate between affected males and unaffected family members  (
         <a class="graphic graphic_figure graphicRef65090" href="/z/d/graphic/65090.html" rel="external">
          figure 4
         </a>
         ).
        </p>
        <p>
         The diagnosis is confirmed by sequencing the
         <em>
          MCT8
         </em>
         gene. A list of laboratories that perform this test is available at the
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fgtr%2F&amp;token=wEsKVFvqlKzpT%2BqOtddW%2Fy3%2BLj0shalBW%2BL1ZyL4tryNPgji1PaJ6Kbd%2Fo1hE9A6&amp;TOPIC_ID=132665" target="_blank">
          Genetic Testing Registry website
         </a>
         .
        </p>
        <p>
         When brain magnetic resonance imaging (MRI) is obtained before the age of two or three years, delayed myelination is typically found [
         <a href="#rid26">
          26
         </a>
         ]. Otherwise, MRI may be normal or show atrophy of the cerebrum, thalamus, corpus callosum, and basal ganglia [
         <a href="#rid9">
          9,11,27-29
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2436542732">
         <span class="h2">
          Treatment
         </span>
         <span class="headingEndMark">
          —
         </span>
         Treatment options for patients with
         <em>
          MCT8
         </em>
         mutations are limited to supportive measures, including the use of braces to prevent contractures. Gastric tube feeding is used for severe weight loss due to difficulties in oral feeding. Diet is adjusted to prevent aspiration, and dystonia is treated with anticholinergics, levodopa,
         <a class="drug drug_pediatric" data-topicid="13113" href="/z/d/drug information/13113.html" rel="external">
          carbamazepine
         </a>
         , and
         <a class="drug drug_pediatric" data-topicid="12983" href="/z/d/drug information/12983.html" rel="external">
          baclofen
         </a>
         . Drooling may respond to treatment with
         <a class="drug drug_pediatric" data-topicid="13338" href="/z/d/drug information/13338.html" rel="external">
          glycopyrrolate
         </a>
         or
         <a class="drug drug_pediatric" data-topicid="16045" href="/z/d/drug information/16045.html" rel="external">
          scopolamine
         </a>
         . Seizures are treated with standard anticonvulsants.
        </p>
        <p>
         Treatment of the low serum T4 concentration with physiologic doses of
         <a class="drug drug_pediatric" data-topicid="12550" href="/z/d/drug information/12550.html" rel="external">
          levothyroxine
         </a>
         is ineffective. This is presumably because of the impaired uptake of the hormone in MCT8-dependent tissues such as brain, while its uptake is preserved in MCT8-independent tissues such as liver (which also has increased deiodinase 1 enzymatic activity, resulting in increased generation of circulating T3). In several cases, one of which has been reported, patients were treated with the combination of
         <a class="drug drug_pediatric" data-topicid="12745" href="/z/d/drug information/12745.html" rel="external">
          propylthiouracil
         </a>
         (in doses that inhibit deiodinase 1 and reduced the amount of T3 generated from T4) with supraphysiologic doses of levothyroxine [
         <a href="#rid30">
          30
         </a>
         ]. This was effective in improving serum thyroid tests and nutrition status.
        </p>
        <p>
         The use of thyroid hormone analogs is a promising new strategy, designed to bypass the molecular defect by using alternative transporters and potentially resolve the issues of thyroid hormone deficiency and excess (thyrotoxicosis) [
         <a href="#rid31">
          31
         </a>
         ]. One such analog, 3,5-diiodothyropropionic acid (DITPA), was studied in a mouse model and was able to ameliorate the brain thyroid hormone deficit without causing thyrotoxic effect in liver [
         <a href="#rid32">
          32
         </a>
         ]. In a pilot study in four children with MCT8 deficiency, treatment with DITPA improved laboratory and clinical abnormalities [
         <a href="#rid33">
          33
         </a>
         ]. In another larger trial, the analog triiodothyroacetic acid (TRIAC) was also associated with improvement in clinical manifestations of thyrotoxicosis [
         <a href="#rid34">
          34
         </a>
         ]. The principal effect is reduction in the circulating T3 level through suppression of TSH and subsequent decrease in thyroid hormone synthesis and secretion. This ameliorates the hypermetabolism and its consequences.
        </p>
        <p>
         Gene therapy is being considered, and preliminary data using a mouse model of THCMTD have shown transfer of the normal human MCT8 to choroid plexus with increased brain T3 and enhanced thyroid hormone effect [
         <a href="#rid35">
          35,36
         </a>
         ].
        </p>
        <p>
         A detailed questionnaire was formulated in collaboration with parents from 15 families to identify clinical endpoints that are relevant to the daily life of individuals with MCT8 deficiency and their caregivers [
         <a href="#rid37">
          37
         </a>
         ]. Improvement in gross motor skills (head control, sitting ability) was most important to the parents, in addition to weight gain; improvement of expressive language skills; and reduction in spasticity, dystonia, dysphagia, and reflux. However, achievement of these goals is challenging, considering the detrimental effect of MCT8 deficiency in utero.
        </p>
        <p class="headingAnchor" id="H520052887">
         <span class="h2">
          Pregnancy
         </span>
         <span class="headingEndMark">
          —
         </span>
         In a family with a known history of an affected child and a known
         <em>
          MCT8
         </em>
         mutation, male fetuses can be assessed in utero for the mutation. If the pregnancy with an affected male embryo is allowed to progress, weekly treatment with 500 mcg of
         <a class="drug drug_pediatric" data-topicid="12550" href="/z/d/drug information/12550.html" rel="external">
          levothyroxine
         </a>
         injected into the amniotic fluid has resulted in improved outcome but not full rescue of the psychoneuromuscular deficit [
         <a href="#rid38">
          38
         </a>
         ]. A trial with DITPA given to the pregnant mother carrying an affected fetus, beginning during the first trimester, is in progress (
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT04143295&amp;token=nbsXe3i4qfUea5RCPRHtOY5G%2FPzFIESeuM6wIJ4nJiR90DMWtAMpstkA2mXz9dLBWaQn0JSSho%2F9DgB8mPHkcA%3D%3D&amp;TOPIC_ID=132665" target="_blank">
          NCT04143295
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H1579325249">
         <span class="h1">
          THYROID HORMONE METABOLISM DEFECT
         </span>
         <span class="headingEndMark">
          —
         </span>
         Thyroid hormone metabolism defect (THMD) is characterized by impaired deiodination of the various iodothyronines.
        </p>
        <p class="headingAnchor" id="H2992502766">
         <span class="h2">
          Genetics
         </span>
         <span class="headingEndMark">
          —
         </span>
         Two inherited forms of THMD have been identified in humans  (
         <a class="graphic graphic_figure graphicRef134209" href="/z/d/graphic/134209.html" rel="external">
          figure 3
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          <em>
           SBP2
          </em>
         </strong>
         <strong>
          gene mutations
         </strong>
         – Biallelic defects in
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F607693&amp;token=87jLzclRwWxNoI%2BQq5Gg79tWWje%2F1%2FoeVmiQI9XcKpW6v7d7iONRuehtkQc1cR6K&amp;TOPIC_ID=132665" target="_blank">
          <i>
           SBP2
          </i>
         </a>
         manifest as partial deficiencies of the three deiodinases, resulting in serum low triiodothyronine (T3) and high thyroxine (T4) and reverse T3 (rT3). SBP2 is required for selenoprotein synthesis, including the three selenoenzyme deiodinases that metabolize thyroid hormone [
         <a href="#rid39">
          39
         </a>
         ]. The incidence of this disorder is unknown. The first three mutations in
         <em>
          SBP2
         </em>
         were reported in 2005 [
         <a href="#rid39">
          39
         </a>
         ]. More families were found subsequently; approximately 20 affected families have been identified worldwide, some of which have not yet been published (communication from AD; manuscript in preparation) [
         <a href="#rid40">
          40-45
         </a>
         ]. The inheritance is recessive, either homozygous or compound heterozygous.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          <em>
           DIO1
          </em>
         </strong>
         <strong>
          gene mutations
         </strong>
         – Heterozygous defects in
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F147892&amp;token=87jLzclRwWxNoI%2BQq5Gg70%2B0Dz0sOGWmPYZSYQ1MrSxV1478VLte3bqo6oeVqXWB&amp;TOPIC_ID=132665" target="_blank">
          <i>
           DIO1
          </i>
         </a>
         produce a high serum rT3:T3 ratio [
         <a href="#rid46">
          46
         </a>
         ].
         <em>
          DIO1
         </em>
         encodes type 1 deiodinase, which participates in the conversion of T4 to T3. Two heterozygous missense mutations in
         <em>
          DIO1
         </em>
         have been described in a case report of two unrelated families [
         <a href="#rid46">
          46
         </a>
         ], and a third mutation was found to act as a phenotype modifier in a family with compound heterozygous thyroid peroxidase (
         <em>
          TPO
         </em>
         ) gene mutations causing congenital hypothyroidism [
         <a href="#rid47">
          47
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Of note, acquired disorders of thyroid hormone metabolism are far more common (eg, the "low T3 syndrome" of nonthyroidal illness) [
         <a href="#rid48">
          48
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H867421">
         <span class="h2">
          Pathogenesis
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Normal intracellular metabolism of thyroid hormone
         </strong>
         – Intracellular iodothyronine metabolism modulates the varying requirements of thyroid hormone, which depend on tissue, cell type, and time. Thyroid hormone is activated and inactivated by site-specific monodeiodination to provide the proper amount of active hormone at its site of action.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Deiodinases are selenoproteins that require a selenocysteine for their enzymatic function. Type 1 and 2 deiodinases catalyze the activation of thyroid hormone by 5'-deiodination that converts to T3. Type 3 deiodinase inactivates T4 and T3 by 5'-deiodination, leading to the generation of rT3 and T2, respectively.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Consequences of SBP2 deficiency
         </strong>
         – Inactivating mutations in the
         <em>
          SBP2
         </em>
         gene prevent incorporation of selenocysteine amino acid into the nascent selenoproteins and thus alter the protein structure and enzymatic activity, causing a global deiodination defect  (
         <a class="graphic graphic_figure graphicRef134209" href="/z/d/graphic/134209.html" rel="external">
          figure 3
         </a>
         ) [
         <a href="#rid49">
          49
         </a>
         ].
         <em>
          SBP2
         </em>
         is located on chromosome 9 and is expressed at a low level in all tissues and at a high level in testis [
         <a href="#rid50">
          50
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Although SBP2 defects cause generalized deficiency of selenoproteins, the initial reports of families with this disorder described a relatively mild phenotype, with abnormal thyroid tests and early growth delay, due to partial SBP2 deficiency and preferential preservation of certain selenoproteins over other selenium-requiring functions [
         <a href="#rid40">
          40,49,51
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Newer case reports describe a broader and more complex phenotype associated with different SBP2 mutations [
         <a href="#rid41">
          41,42
         </a>
         ]. These mutations caused a severe SBP2 deficiency, resulting in reduced synthesis of most of the 25 known human selenoproteins, which alter diverse biologic processes. (See
         <a class="local">
          'Clinical features'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1805275760">
         <span class="h2">
          Clinical features
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with partial SBP2 deficiency have come to medical attention during childhood because of short stature and delayed bone age. These features prompted thyroid function testing, leading to the identification of thyroid abnormalities [
         <a href="#rid39">
          39
         </a>
         ]. Pregnancy and birth were normal. In one case, the neonatal screen showed an elevated thyroid-stimulating hormone (TSH) level with high-normal T4.
        </p>
        <p>
         In patients with more severe SBP2 deficiency, a wider variety of abnormalities may be seen [
         <a href="#rid41">
          41,42
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Male infertility with azoospermia.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Axial muscular dystrophy with impaired motor coordination.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Intellectual disability.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hearing impairment.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Photosensitivity and susceptibility to ultraviolet radiation-induced oxidative damage.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Abnormal immune cell function – Impaired T lymphocyte proliferation, abnormal mononuclear cell cytokine secretion (excess interleukin-6, excess tumor necrosis factor-alpha, and reduced interferon-gamma), and telomere shortening.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Enhanced systemic and cellular insulin sensitivity [
         <a href="#rid41">
          41
         </a>
         ]. This was associated with raised reactive oxygen species, similar to findings in antioxidant selenoenzyme (GPx1) knockout mice.
        </p>
        <p>
        </p>
        <p>
         In some of these patients, multiple tissues and organs show damage mediated by reactive oxygen species [
         <a href="#rid41">
          41
         </a>
         ] and it is conceivable that other pathologies linked to oxidative damage such as neoplasia, neurodegeneration, and premature aging may manifest with time.
        </p>
        <p class="headingAnchor" id="H2661418207">
         <span class="h2">
          Laboratory findings
         </span>
         <span class="headingEndMark">
          —
         </span>
         Typical laboratory findings are high T4, low T3, high rT3, and normal or slightly elevated serum TSH. A comparison with the other three syndromes of impaired sensitivity to thyroid hormone is shown in the table  (
         <a class="graphic graphic_table graphicRef50619" href="/z/d/graphic/50619.html" rel="external">
          table 2
         </a>
         ). No other hormonal abnormalities have been detected, and serum insulin-like growth factor 1 (IGF-1) concentrations are normal despite delayed growth.
        </p>
        <p>
         Serum concentrations of
         <a class="drug drug_pediatric" data-topicid="98778" href="/z/d/drug information/98778.html" rel="external">
          selenium
         </a>
         , selenoprotein P, and other selenoproteins are reduced. Skin fibroblasts have low selenoenzyme type 2 deiodinase activity but normal mRNA content, reflecting a defect in selenoenzyme synthesis [
         <a href="#rid39">
          39
         </a>
         ]. One patient was reported to have higher serum levels of free radical-mediated lipid peroxidation products such as 7-beta-hydroxycholesterol than did controls [
         <a href="#rid52">
          52
         </a>
         ].
        </p>
        <p>
         Detailed evaluation of two cases with severe SBP2 deficiency demonstrated deficiencies in multiple selenoproteins [
         <a href="#rid41">
          41
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Lack of testis-enriched selenoproteins, causing failure of the latter stages of spermatogenesis and azoospermia
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Selenoprotein N (SELENON)-like myopathy, causing axial muscular dystrophy
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cutaneous deficiencies of antioxidant selenoenzymes, causing increased cellular reactive oxygen species and photosensitivity
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Reduced selenoproteins in peripheral blood cells, causing immune deficits [
         <a href="#rid41">
          41
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Deficiencies of other selenoproteins with unknown function (SELH, SELT, SELW, SELI) were also found, the consequences of which are not yet known
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3613063455">
         <span class="h2">
          Treatment
         </span>
         <span class="headingEndMark">
          —
         </span>
         No specific treatment is available, but several interventions appear to correct some of the related abnormalities, based on very limited evidence from case reports:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_pediatric" data-topicid="12557" href="/z/d/drug information/12557.html" rel="external">
          Liothyronine
         </a>
         appeared to correct delayed linear growth [
         <a href="#rid40">
          40
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Growth hormone administration improved height but was not able to compensate for the effects of T3 on bone maturation [
         <a href="#rid43">
          43
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Administration of
         <a class="drug drug_pediatric" data-topicid="12884" href="/z/d/drug information/12884.html" rel="external">
          vitamin E
         </a>
         (alpha-tocopherol acetate) in a dose of 100 mg/day for two years normalized serum lipid peroxidation product levels, while withdrawal of this regimen for seven months reversed this effect [
         <a href="#rid52">
          52
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Administration of up to 400 mcg of
         <a class="drug drug_pediatric" data-topicid="98778" href="/z/d/drug information/98778.html" rel="external">
          selenium
         </a>
         normalized the serum selenium concentration but had no effect on selenoprotein type 2 deiodinase activity and glutathione peroxidase concentration and failed to correct the abnormalities of serum iodothyronine levels [
         <a href="#rid53">
          53
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3120783458">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Causes of impaired sensitivity to thyroid hormone
         </strong>
         – Impaired sensitivity to thyroid hormone is seen in several inherited syndromes, with distinct mechanisms (see
         <a class="local">
          'Mechanisms of impaired sensitivity'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Thyroid hormone cell membrane transport defect (THCMTD) and thyroid hormone metabolism defect (THMD) are rare defects that cause reduced intracellular levels of thyroid hormone in a cell-specific manner, depending on the redundancy in transmembrane thyroid hormone transporters and the deiodinases expressed locally in various tissues.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Resistance to thyroid hormone (RTH) is more common and is characterized by impaired thyroid hormone action, usually caused by a mutation in the genes encoding the thyroid hormone receptors. The types and clinical characteristics of RTH are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/5827.html" rel="external">
          "Resistance to thyroid hormone and other defects in thyroid hormone action"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         These disorders can be distinguished by their characteristic abnormalities of serum thyroid function tests  (
         <a class="graphic graphic_table graphicRef50619" href="/z/d/graphic/50619.html" rel="external">
          table 2
         </a>
         ). In each disorder, mutations in a single gene are responsible for most or all identified cases  (
         <a class="graphic graphic_table graphicRef110783" href="/z/d/graphic/110783.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          THCMTD
         </strong>
         – THCMTD is characterized by inadequate transport of thyroid hormone into some target cells, resulting in reduced intracellular levels of thyroid hormone, and an excess of intracellular hormone in cells that express alternative transporters.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The only identified THCMTD is an X-linked mutation in
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F300095&amp;token=87jLzclRwWxNoI%2BQq5Gg777eE%2F3d0TdyiA30Y9NC13O4PCI7jJzYhrpF3PxWs%2BQd&amp;TOPIC_ID=132665" target="_blank">
          <i>
           MCT8
          </i>
         </a>
         , the gene encoding monocarboxylate transporter 8. (See
         <a class="local">
          'Thyroid hormone cell membrane transport defect'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Typical laboratory findings of MCT8 deficiency are high serum triiodothyronine (T3) and low reverse T3 (rT3) concentrations; this pattern is distinct from other causes of reduced sensitivity to thyroid hormone  (
         <a class="graphic graphic_table graphicRef50619" href="/z/d/graphic/50619.html" rel="external">
          table 2
         </a>
         ). (See
         <a class="local">
          'Laboratory findings'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The early hallmarks of MCT8 defects are hypotonia and high serum T3 levels in male infants. Affected individuals have stigmata of thyroid hormone deficiency, including severe neurodevelopmental abnormalities, as well as thyroid hormone excess, manifesting as inability to gain weight independent of nutrition. Carrier females have intermediate thyroid hormone concentrations and are asymptomatic. (See
         <a class="local">
          'Clinical features'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Treatment options for patients with
         <em>
          MCT8
         </em>
         mutations are limited to supportive measures; treatment of the low serum thyroxine (T4) concentration with physiologic doses of
         <a class="drug drug_pediatric" data-topicid="12550" href="/z/d/drug information/12550.html" rel="external">
          levothyroxine
         </a>
         has been ineffective. (See
         <a class="local">
          'Treatment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          THMD
         </strong>
         – THMD is characterized by impaired activity of the deiodinases that metabolize the different iodothyronines T4, T3, and rT3. (See
         <a class="local">
          'Thyroid hormone metabolism defect'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         THMD can be caused by biallelic mutations in the
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F607693&amp;token=87jLzclRwWxNoI%2BQq5Gg79tWWje%2F1%2FoeVmiQI9XcKpW6v7d7iONRuehtkQc1cR6K&amp;TOPIC_ID=132665" target="_blank">
          <i>
           SBP2
          </i>
         </a>
         (
         <em>
          SECISBP2
         </em>
         ) gene or heterozygous mutations in the
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F147892&amp;token=87jLzclRwWxNoI%2BQq5Gg70%2B0Dz0sOGWmPYZSYQ1MrSxV1478VLte3bqo6oeVqXWB&amp;TOPIC_ID=132665" target="_blank">
          <i>
           DIO1
          </i>
         </a>
         gene.
         <em>
          SBP2
         </em>
         mutations interfere with selenoprotein synthesis and have been identified in 20 families. Only three families with mutations in
         <em>
          DIO1
         </em>
         have been reported. (See
         <a class="local">
          'Genetics'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Clinical features of THMD are (see
         <a class="local">
          'Clinical features'
         </a>
         above and
         <a class="local">
          'Laboratory findings'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Biallelic
         <em>
          SBP2
         </em>
         defects are associated with high T4, low T3, high rT3, normal or slightly elevated serum thyroid-stimulating hormone (TSH)  (
         <a class="graphic graphic_table graphicRef50619" href="/z/d/graphic/50619.html" rel="external">
          table 2
         </a>
         ), decreased serum
         <a class="drug drug_pediatric" data-topicid="98778" href="/z/d/drug information/98778.html" rel="external">
          selenium
         </a>
         , and decreased selenoprotein levels and activity in serum and tissues. The clinical phenotype is complex and depends on the severity of the
         <em>
          SBP2
         </em>
         defect. Affected individuals may have delayed growth and puberty and, in severe cases, failure to thrive, intellectual disability, infertility, myopathy, hearing impairment, photosensitivity, and immune deficits.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Heterozygous
         <em>
          DIO1
         </em>
         mutations are associated with increased serum rT3:T3 ratio and, possibly, increased cholesterol but no distinctive clinical abnormalities.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2520031008">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Roy E Weiss, MD, PhD, who contributed to earlier versions of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Refetoff S, Bassett JH, Beck-Peccoz P, et al. Classification and proposed nomenclature for inherited defects of thyroid hormone action, cell transport, and metabolism. Thyroid 2014; 24:407.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Refetoff S, Bassett JH, Beck-Peccoz P, et al. Classification and proposed nomenclature for inherited defects of thyroid hormone action, cell transport, and metabolism. J Clin Endocrinol Metab 2014; 99:768.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Refetoff S, Bassett JH, Beck-Peccoz P, et al. Classification and proposed nomenclature for inherited defects of thyroid hormone action, cell transport, and metabolism. Eur Thyroid J 2014; 3:7.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dumitrescu AM, Liao XH, Best TB, et al. A novel syndrome combining thyroid and neurological abnormalities is associated with mutations in a monocarboxylate transporter gene. Am J Hum Genet 2004; 74:168.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Di Cosmo C, Liao XH, Dumitrescu AM, et al. Mice deficient in MCT8 reveal a mechanism regulating thyroid hormone secretion. J Clin Invest 2010; 120:3377.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Trajkovic-Arsic M, Visser TJ, Darras VM, et al. Consequences of monocarboxylate transporter 8 deficiency for renal transport and metabolism of thyroid hormones in mice. Endocrinology 2010; 151:802.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Allan W, Herndon CN, Dudley FC. Some examples of the inheritance of mental deficiency: apparently sex-linked idiocy and microcephaly. Am J Ment Defic 1944; 48:325.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Friesema EC, Grueters A, Biebermann H, et al. Association between mutations in a thyroid hormone transporter and severe X-linked psychomotor retardation. Lancet 2004; 364:1435.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kakinuma H, Itoh M, Takahashi H. A novel mutation in the monocarboxylate transporter 8 gene in a boy with putamen lesions and low free T4 levels in cerebrospinal fluid. J Pediatr 2005; 147:552.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Visser WE, Friesema EC, Jansen J, Visser TJ. Thyroid hormone transport in and out of cells. Trends Endocrinol Metab 2008; 19:50.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Papadimitriou A, Dumitrescu AM, Papavasiliou A, et al. A novel monocarboxylate transporter 8 gene mutation as a cause of severe neonatal hypotonia and developmental delay. Pediatrics 2008; 121:e199.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Frints SG, Lenzner S, Bauters M, et al. MCT8 mutation analysis and identification of the first female with Allan-Herndon-Dudley syndrome due to loss of MCT8 expression. Eur J Hum Genet 2008; 16:1029.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Iwayama H, Kakita H, Iwasa M, et al. Measurement of Reverse Triiodothyronine Level and the Triiodothyronine to Reverse Triiodothyronine Ratio in Dried Blood Spot Samples at Birth May Facilitate Early Detection of Monocarboxylate Transporter 8 Deficiency. Thyroid 2021; 31:1316.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Friesema EC, Ganguly S, Abdalla A, et al. Identification of monocarboxylate transporter 8 as a specific thyroid hormone transporter. J Biol Chem 2003; 278:40128.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heuer H, Visser TJ. Minireview: Pathophysiological importance of thyroid hormone transporters. Endocrinology 2009; 150:1078.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           López-Espíndola D, Morales-Bastos C, Grijota-Martínez C, et al. Mutations of the thyroid hormone transporter MCT8 cause prenatal brain damage and persistent hypomyelination. J Clin Endocrinol Metab 2014; 99:E2799.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jansen J, Friesema EC, Kester MH, et al. Genotype-phenotype relationship in patients with mutations in thyroid hormone transporter MCT8. Endocrinology 2008; 149:2184.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dumitrescu AM, Liao XH, Weiss RE, et al. Tissue-specific thyroid hormone deprivation and excess in monocarboxylate transporter (mct) 8-deficient mice. Endocrinology 2006; 147:4036.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Trajkovic M, Visser TJ, Mittag J, et al. Abnormal thyroid hormone metabolism in mice lacking the monocarboxylate transporter 8. J Clin Invest 2007; 117:627.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bernal J. Role of monocarboxylate anion transporter 8 (MCT8) in thyroid hormone transport: Answers from mice. Endocrinology 2006; 147:4034.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hennemann G, Docter R, Friesema EC, et al. Plasma membrane transport of thyroid hormones and its role in thyroid hormone metabolism and bioavailability. Endocr Rev 2001; 22:451.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Friesema EC, Jansen J, Milici C, Visser TJ. Thyroid hormone transporters. Vitam Horm 2005; 70:137.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brockmann K, Dumitrescu AM, Best TT, et al. X-linked paroxysmal dyskinesia and severe global retardation caused by defective MCT8 gene. J Neurol 2005; 252:663.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Solazzi R, Nanni G, Esposito S, et al. Repetitive Sleep Starts in Allan-Herndon-Dudley Syndrome. Pediatr Neurol 2023; 147:24.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Groeneweg S, van Geest FS, Abacı A, et al. Disease characteristics of MCT8 deficiency: an international, retrospective, multicentre cohort study. Lancet Diabetes Endocrinol 2020; 8:594.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gika AD, Siddiqui A, Hulse AJ, et al. White matter abnormalities and dystonic motor disorder associated with mutations in the SLC16A2 gene. Dev Med Child Neurol 2010; 52:475.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Holden KR, Zuñiga OF, May MM, et al. X-linked MCT8 gene mutations: characterization of the pediatric neurologic phenotype. J Child Neurol 2005; 20:852.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Namba N, Etani Y, Kitaoka T, et al. Clinical phenotype and endocrinological investigations in a patient with a mutation in the MCT8 thyroid hormone transporter. Eur J Pediatr 2008; 167:785.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vaurs-Barrière C, Deville M, Sarret C, et al. Pelizaeus-Merzbacher-Like disease presentation of MCT8 mutated male subjects. Ann Neurol 2009; 65:114.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wémeau JL, Pigeyre M, Proust-Lemoine E, et al. Beneficial effects of propylthiouracil plus L-thyroxine treatment in a patient with a mutation in MCT8. J Clin Endocrinol Metab 2008; 93:2084.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grijota-Martínez C, Bárez-López S, Gómez-Andrés D, Guadaño-Ferraz A. MCT8 Deficiency: The Road to Therapies for a Rare Disease. Front Neurosci 2020; 14:380.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Di Cosmo C, Liao XH, Dumitrescu AM, et al. A thyroid hormone analog with reduced dependence on the monocarboxylate transporter 8 for tissue transport. Endocrinology 2009; 150:4450.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Verge CF, Konrad D, Cohen M, et al. Diiodothyropropionic acid (DITPA) in the treatment of MCT8 deficiency. J Clin Endocrinol Metab 2012; 97:4515.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Groeneweg S, Peeters RP, Moran C, et al. Effectiveness and safety of the tri-iodothyronine analogue Triac in children and adults with MCT8 deficiency: an international, single-arm, open-label, phase 2 trial. Lancet Diabetes Endocrinol 2019; 7:695.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Iwayama H, Liao XH, Braun L, et al. Adeno Associated Virus 9-Based Gene Therapy Delivers a Functional Monocarboxylate Transporter 8, Improving Thyroid Hormone Availability to the Brain of Mct8-Deficient Mice. Thyroid 2016; 26:1311.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sundaram SM, Arrulo Pereira A, Müller-Fielitz H, et al. Gene therapy targeting the blood-brain barrier improves neurological symptoms in a model of genetic MCT8 deficiency. Brain 2022; 145:4264.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wilpert NM, Tonduti D, Vaia Y, et al. Establishing Patient-Centered Outcomes for MCT8 Deficiency: Stakeholder Engagement and Systematic Literature Review. Neuropsychiatr Dis Treat 2023; 19:2195.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Refetoff S, Pappa T, Williams MK, et al. Prenatal Treatment of Thyroid Hormone Cell Membrane Transport Defect Caused by MCT8 Gene Mutation. Thyroid 2021; 31:713.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dumitrescu AM, Liao XH, Abdullah MS, et al. Mutations in SECISBP2 result in abnormal thyroid hormone metabolism. Nat Genet 2005; 37:1247.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Di Cosmo C, McLellan N, Liao XH, et al. Clinical and molecular characterization of a novel selenocysteine insertion sequence-binding protein 2 (SBP2) gene mutation (R128X). J Clin Endocrinol Metab 2009; 94:4003.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schoenmakers E, Agostini M, Mitchell C, et al. Mutations in the selenocysteine insertion sequence-binding protein 2 gene lead to a multisystem selenoprotein deficiency disorder in humans. J Clin Invest 2010; 120:4220.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Azevedo MF, Barra GB, Naves LA, et al. Selenoprotein-related disease in a young girl caused by nonsense mutations in the SBP2 gene. J Clin Endocrinol Metab 2010; 95:4066.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hamajima T, Mushimoto Y, Kobayashi H, et al. Novel compound heterozygous mutations in the SBP2 gene: characteristic clinical manifestations and the implications of GH and triiodothyronine in longitudinal bone growth and maturation. Eur J Endocrinol 2012; 166:757.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Çatli G, Fujisawa H, Kirbiyik Ö, et al. A Novel Homozygous Selenocysteine Insertion Sequence Binding Protein 2 (SECISBP2, SBP2) Gene Mutation in a Turkish Boy. Thyroid 2018; 28:1221.
          </a>
         </li>
         <li class="breakAll">
          Dumitrescu AM, Korwutthikulrangsri M, Refetoff S. Impaired sensitivity to thyroid hormone: defects of transport, metabolism, and action. In: Werner &amp; Ingbar's The Thyroid: A Fundamental and Clinical Text, 11th ed, Braverman LE, Cooper DS, Kopp PA (Eds), Lippincott Williams &amp; Wilkins, 2021. p.868.
         </li>
         <li>
          <a class="nounderline abstract_t">
           França MM, German A, Fernandes GW, et al. Human Type 1 Iodothyronine Deiodinase (DIO1) Mutations Cause Abnormal Thyroid Hormone Metabolism. Thyroid 2021; 31:202.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Furman A, Hannoush Z, Echegoyen FB, et al. Novel DIO1 Gene Mutation Acting as Phenotype Modifier for Novel Compound Heterozygous TPO Gene Mutations Causing Congenital Hypothyroidism. Thyroid 2021; 31:1589.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koenig RJ. Regulation of type 1 iodothyronine deiodinase in health and disease. Thyroid 2005; 15:835.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Copeland PR. Regulation of gene expression by stop codon recoding: selenocysteine. Gene 2003; 312:17.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lescure A, Allmang C, Yamada K, et al. cDNA cloning, expression pattern and RNA binding analysis of human selenocysteine insertion sequence (SECIS) binding protein 2. Gene 2002; 291:279.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Köhrle J. Selenium and the control of thyroid hormone metabolism. Thyroid 2005; 15:841.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saito Y, Shichiri M, Hamajima T, et al. Enhancement of lipid peroxidation and its amelioration by vitamin E in a subject with mutations in the SBP2 gene. J Lipid Res 2015; 56:2172.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schomburg L, Dumitrescu AM, Liao XH, et al. Selenium supplementation fails to correct the selenoprotein synthesis defect in subjects with SBP2 gene mutations. Thyroid 2009; 19:277.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 132665 Version 7.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24588711" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Classification and proposed nomenclature for inherited defects of thyroid hormone action, cell transport, and metabolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24823702" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Classification and proposed nomenclature for inherited defects of thyroid hormone action, cell transport, and metabolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24847459" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Classification and proposed nomenclature for inherited defects of thyroid hormone action, cell transport, and metabolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14661163" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : A novel syndrome combining thyroid and neurological abnormalities is associated with mutations in a monocarboxylate transporter gene.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20679730" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Mice deficient in MCT8 reveal a mechanism regulating thyroid hormone secretion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19996182" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Consequences of monocarboxylate transporter 8 deficiency for renal transport and metabolism of thyroid hormones in mice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Some examples of the inheritance of mental deficiency: apparently sex-linked idiocy and microcephaly
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15488219" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Association between mutations in a thyroid hormone transporter and severe X-linked psychomotor retardation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16227048" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : A novel mutation in the monocarboxylate transporter 8 gene in a boy with putamen lesions and low free T4 levels in cerebrospinal fluid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18291666" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Thyroid hormone transport in and out of cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18166539" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : A novel monocarboxylate transporter 8 gene mutation as a cause of severe neonatal hypotonia and developmental delay.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18398436" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : MCT8 mutation analysis and identification of the first female with Allan-Herndon-Dudley syndrome due to loss of MCT8 expression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34049438" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Measurement of Reverse Triiodothyronine Level and the Triiodothyronine to Reverse Triiodothyronine Ratio in Dried Blood Spot Samples at Birth May Facilitate Early Detection of Monocarboxylate Transporter 8 Deficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12871948" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Identification of monocarboxylate transporter 8 as a specific thyroid hormone transporter.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19179441" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Minireview: Pathophysiological importance of thyroid hormone transporters.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25222753" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Mutations of the thyroid hormone transporter MCT8 cause prenatal brain damage and persistent hypomyelination.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18187543" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Genotype-phenotype relationship in patients with mutations in thyroid hormone transporter MCT8.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16709608" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Tissue-specific thyroid hormone deprivation and excess in monocarboxylate transporter (mct) 8-deficient mice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17318265" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Abnormal thyroid hormone metabolism in mice lacking the monocarboxylate transporter 8.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16912236" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Role of monocarboxylate anion transporter 8 (MCT8) in thyroid hormone transport: Answers from mice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11493579" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Plasma membrane transport of thyroid hormones and its role in thyroid hormone metabolism and bioavailability.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15727804" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Thyroid hormone transporters.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15834651" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : X-linked paroxysmal dyskinesia and severe global retardation caused by defective MCT8 gene.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37542971" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Repetitive Sleep Starts in Allan-Herndon-Dudley Syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32559475" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Disease characteristics of MCT8 deficiency: an international, retrospective, multicentre cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19811520" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : White matter abnormalities and dystonic motor disorder associated with mutations in the SLC16A2 gene.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16417886" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : X-linked MCT8 gene mutations: characterization of the pediatric neurologic phenotype.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17899191" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Clinical phenotype and endocrinological investigations in a patient with a mutation in the MCT8 thyroid hormone transporter.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19194886" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Pelizaeus-Merzbacher-Like disease presentation of MCT8 mutated male subjects.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18334584" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Beneficial effects of propylthiouracil plus L-thyroxine treatment in a patient with a mutation in MCT8.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32410949" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : MCT8 Deficiency: The Road to Therapies for a Rare Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19497976" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : A thyroid hormone analog with reduced dependence on the monocarboxylate transporter 8 for tissue transport.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22993035" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Diiodothyropropionic acid (DITPA) in the treatment of MCT8 deficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31377265" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Effectiveness and safety of the tri-iodothyronine analogue Triac in children and adults with MCT8 deficiency: an international, single-arm, open-label, phase 2 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27432638" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Adeno Associated Virus 9-Based Gene Therapy Delivers a Functional Monocarboxylate Transporter 8, Improving Thyroid Hormone Availability to the Brain of Mct8-Deficient Mice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35929549" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Gene therapy targeting the blood-brain barrier improves neurological symptoms in a model of genetic MCT8 deficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37881807" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Establishing Patient-Centered Outcomes for MCT8 Deficiency: Stakeholder Engagement and Systematic Literature Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32746752" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Prenatal Treatment of Thyroid Hormone Cell Membrane Transport Defect Caused by MCT8 Gene Mutation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16228000" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Mutations in SECISBP2 result in abnormal thyroid hormone metabolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19602558" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Clinical and molecular characterization of a novel selenocysteine insertion sequence-binding protein 2 (SBP2) gene mutation (R128X).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21084748" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Mutations in the selenocysteine insertion sequence-binding protein 2 gene lead to a multisystem selenoprotein deficiency disorder in humans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20501692" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Selenoprotein-related disease in a young girl caused by nonsense mutations in the SBP2 gene.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22247018" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Novel compound heterozygous mutations in the SBP2 gene: characteristic clinical manifestations and the implications of GH and triiodothyronine in longitudinal bone growth and maturation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29882503" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : A Novel Homozygous Selenocysteine Insertion Sequence Binding Protein 2 (SECISBP2, SBP2) Gene Mutation in a Turkish Boy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29882503" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : A Novel Homozygous Selenocysteine Insertion Sequence Binding Protein 2 (SECISBP2, SBP2) Gene Mutation in a Turkish Boy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32718224" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Human Type 1 Iodothyronine Deiodinase (DIO1) Mutations Cause Abnormal Thyroid Hormone Metabolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34128397" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Novel DIO1 Gene Mutation Acting as Phenotype Modifier for Novel Compound Heterozygous TPO Gene Mutations Causing Congenital Hypothyroidism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16131326" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Regulation of type 1 iodothyronine deiodinase in health and disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12909337" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Regulation of gene expression by stop codon recoding: selenocysteine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12095701" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : cDNA cloning, expression pattern and RNA binding analysis of human selenocysteine insertion sequence (SECIS) binding protein 2.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16131327" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Selenium and the control of thyroid hormone metabolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26411970" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Enhancement of lipid peroxidation and its amelioration by vitamin E in a subject with mutations in the SBP2 gene.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19265499" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Selenium supplementation fails to correct the selenoprotein synthesis defect in subjects with SBP2 gene mutations.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
